2025-04-22 2026-03-31 2026-03-31 false 16398946 WARWICKER NEPHROLOGY LIMITED 2026-04-15 false iso4217:GBP xbrli:pure 16398946 2025-04-21 16398946 2026-03-31 16398946 2025-04-22 2026-03-31 16398946 2025-04-20 16398946 2025-04-21 16398946 2025-04-21 2025-04-21 16398946 bus:SmallEntities 2025-04-22 2026-03-31 16398946 bus:AuditExempt-NoAccountantsReport 2025-04-22 2026-03-31 16398946 bus:AbridgedAccounts 2025-04-22 2026-03-31 16398946 bus:PrivateLimitedCompanyLtd 2025-04-22 2026-03-31 16398946 core:WithinOneYear 2026-03-31 16398946 core:AfterOneYear 2026-03-31 16398946 core:WithinOneYear 2025-04-21 16398946 core:AfterOneYear 2025-04-21 16398946 core:ShareCapital 2026-03-31 16398946 core:SharePremium 2026-03-31 16398946 core:RevaluationReserve 2026-03-31 16398946 core:OtherReservesSubtotal 2026-03-31 16398946 core:RetainedEarningsAccumulatedLosses 2026-03-31 16398946 core:ShareCapital 2025-04-21 16398946 core:SharePremium 2025-04-21 16398946 core:RevaluationReserve 2025-04-21 16398946 core:OtherReservesSubtotal 2025-04-21 16398946 core:RetainedEarningsAccumulatedLosses 2025-04-21 16398946 core:LandBuildings 2026-03-31 16398946 core:PlantMachinery 2026-03-31 16398946 core:Vehicles 2026-03-31 16398946 core:FurnitureFittings 2026-03-31 16398946 core:OfficeEquipment 2026-03-31 16398946 core:NetGoodwill 2026-03-31 16398946 core:IntangibleAssetsOtherThanGoodwill 2026-03-31 16398946 core:ListedExchangeTraded 2026-03-31 16398946 core:UnlistedNon-exchangeTraded 2026-03-31 16398946 core:LandBuildings 2025-04-21 16398946 core:PlantMachinery 2025-04-21 16398946 core:Vehicles 2025-04-21 16398946 core:FurnitureFittings 2025-04-21 16398946 core:OfficeEquipment 2025-04-21 16398946 core:NetGoodwill 2025-04-21 16398946 core:IntangibleAssetsOtherThanGoodwill 2025-04-21 16398946 core:ListedExchangeTraded 2025-04-21 16398946 core:UnlistedNon-exchangeTraded 2025-04-21 16398946 core:LandBuildings 2025-04-22 2026-03-31 16398946 core:PlantMachinery 2025-04-22 2026-03-31 16398946 core:Vehicles 2025-04-22 2026-03-31 16398946 core:FurnitureFittings 2025-04-22 2026-03-31 16398946 core:OfficeEquipment 2025-04-22 2026-03-31 16398946 core:NetGoodwill 2025-04-22 2026-03-31 16398946 core:IntangibleAssetsOtherThanGoodwill 2025-04-22 2026-03-31 16398946 core:ListedExchangeTraded 2025-04-22 2026-03-31 16398946 core:UnlistedNon-exchangeTraded 2025-04-22 2026-03-31 16398946 core:MoreThanFiveYears 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments 2026-03-31 16398946 core:Non-currentFinancialInstruments 2025-04-21 16398946 dpl:CostSales 2025-04-22 2026-03-31 16398946 dpl:DistributionCosts 2025-04-22 2026-03-31 16398946 core:LandBuildings 2025-04-22 2026-03-31 16398946 core:PlantMachinery 2025-04-22 2026-03-31 16398946 core:Vehicles 2025-04-22 2026-03-31 16398946 core:FurnitureFittings 2025-04-22 2026-03-31 16398946 core:OfficeEquipment 2025-04-22 2026-03-31 16398946 dpl:AdministrativeExpenses 2025-04-22 2026-03-31 16398946 core:NetGoodwill 2025-04-22 2026-03-31 16398946 core:IntangibleAssetsOtherThanGoodwill 2025-04-22 2026-03-31 16398946 dpl:GroupUndertakings 2025-04-22 2026-03-31 16398946 dpl:ParticipatingInterests 2025-04-22 2026-03-31 16398946 dpl:GroupUndertakings core:ListedExchangeTraded 2025-04-22 2026-03-31 16398946 core:ListedExchangeTraded 2025-04-22 2026-03-31 16398946 dpl:GroupUndertakings core:UnlistedNon-exchangeTraded 2025-04-22 2026-03-31 16398946 core:UnlistedNon-exchangeTraded 2025-04-22 2026-03-31 16398946 dpl:CostSales 2025-04-21 2025-04-21 16398946 dpl:DistributionCosts 2025-04-21 2025-04-21 16398946 core:LandBuildings 2025-04-21 2025-04-21 16398946 core:PlantMachinery 2025-04-21 2025-04-21 16398946 core:Vehicles 2025-04-21 2025-04-21 16398946 core:FurnitureFittings 2025-04-21 2025-04-21 16398946 core:OfficeEquipment 2025-04-21 2025-04-21 16398946 dpl:AdministrativeExpenses 2025-04-21 2025-04-21 16398946 core:NetGoodwill 2025-04-21 2025-04-21 16398946 core:IntangibleAssetsOtherThanGoodwill 2025-04-21 2025-04-21 16398946 dpl:GroupUndertakings 2025-04-21 2025-04-21 16398946 dpl:ParticipatingInterests 2025-04-21 2025-04-21 16398946 dpl:GroupUndertakings core:ListedExchangeTraded 2025-04-21 2025-04-21 16398946 core:ListedExchangeTraded 2025-04-21 2025-04-21 16398946 dpl:GroupUndertakings core:UnlistedNon-exchangeTraded 2025-04-21 2025-04-21 16398946 core:UnlistedNon-exchangeTraded 2025-04-21 2025-04-21 16398946 core:NetGoodwill 2026-03-31 16398946 core:IntangibleAssetsOtherThanGoodwill 2026-03-31 16398946 core:LandBuildings 2026-03-31 16398946 core:PlantMachinery 2026-03-31 16398946 core:Vehicles 2026-03-31 16398946 core:FurnitureFittings 2026-03-31 16398946 core:OfficeEquipment 2026-03-31 16398946 core:AfterOneYear 2026-03-31 16398946 core:WithinOneYear 2026-03-31 16398946 core:ListedExchangeTraded 2026-03-31 16398946 core:UnlistedNon-exchangeTraded 2026-03-31 16398946 core:ShareCapital 2026-03-31 16398946 core:SharePremium 2026-03-31 16398946 core:RevaluationReserve 2026-03-31 16398946 core:OtherReservesSubtotal 2026-03-31 16398946 core:RetainedEarningsAccumulatedLosses 2026-03-31 16398946 core:NetGoodwill 2025-04-21 16398946 core:IntangibleAssetsOtherThanGoodwill 2025-04-21 16398946 core:LandBuildings 2025-04-21 16398946 core:PlantMachinery 2025-04-21 16398946 core:Vehicles 2025-04-21 16398946 core:FurnitureFittings 2025-04-21 16398946 core:OfficeEquipment 2025-04-21 16398946 core:AfterOneYear 2025-04-21 16398946 core:WithinOneYear 2025-04-21 16398946 core:ListedExchangeTraded 2025-04-21 16398946 core:UnlistedNon-exchangeTraded 2025-04-21 16398946 core:ShareCapital 2025-04-21 16398946 core:SharePremium 2025-04-21 16398946 core:RevaluationReserve 2025-04-21 16398946 core:OtherReservesSubtotal 2025-04-21 16398946 core:RetainedEarningsAccumulatedLosses 2025-04-21 16398946 core:NetGoodwill 2025-04-20 16398946 core:IntangibleAssetsOtherThanGoodwill 2025-04-20 16398946 core:LandBuildings 2025-04-20 16398946 core:PlantMachinery 2025-04-20 16398946 core:Vehicles 2025-04-20 16398946 core:FurnitureFittings 2025-04-20 16398946 core:OfficeEquipment 2025-04-20 16398946 core:AfterOneYear 2025-04-20 16398946 core:WithinOneYear 2025-04-20 16398946 core:ListedExchangeTraded 2025-04-20 16398946 core:UnlistedNon-exchangeTraded 2025-04-20 16398946 core:ShareCapital 2025-04-20 16398946 core:SharePremium 2025-04-20 16398946 core:RevaluationReserve 2025-04-20 16398946 core:OtherReservesSubtotal 2025-04-20 16398946 core:RetainedEarningsAccumulatedLosses 2025-04-20 16398946 core:AfterOneYear 2025-04-22 2026-03-31 16398946 core:WithinOneYear 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:CostValuation 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:AdditionsToInvestments 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:DisposalsDecreaseInInvestments 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:ImpairmentLossReversalProvisionsForImpairmentInvestments 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:AcquisitionsIncreaseInProvisionsForImpairmentInvestments 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:DisposalsDecreaseInProvisionsForImpairmentInvestments 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments 2025-04-22 2026-03-31 16398946 core:Non-currentFinancialInstruments core:CostValuation 2026-03-31 16398946 core:Non-currentFinancialInstruments core:AdditionsToInvestments 2026-03-31 16398946 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2026-03-31 16398946 core:Non-currentFinancialInstruments core:DisposalsDecreaseInInvestments 2026-03-31 16398946 core:Non-currentFinancialInstruments core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2026-03-31 16398946 core:Non-currentFinancialInstruments core:ImpairmentLossReversalProvisionsForImpairmentInvestments 2026-03-31 16398946 core:Non-currentFinancialInstruments core:AcquisitionsIncreaseInProvisionsForImpairmentInvestments 2026-03-31 16398946 core:Non-currentFinancialInstruments core:DisposalsDecreaseInProvisionsForImpairmentInvestments 2026-03-31 16398946 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments 2026-03-31 16398946 core:Non-currentFinancialInstruments core:CostValuation 2025-04-21 16398946 core:Non-currentFinancialInstruments core:AdditionsToInvestments 2025-04-21 16398946 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2025-04-21 16398946 core:Non-currentFinancialInstruments core:DisposalsDecreaseInInvestments 2025-04-21 16398946 core:Non-currentFinancialInstruments core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2025-04-21 16398946 core:Non-currentFinancialInstruments core:ImpairmentLossReversalProvisionsForImpairmentInvestments 2025-04-21 16398946 core:Non-currentFinancialInstruments core:AcquisitionsIncreaseInProvisionsForImpairmentInvestments 2025-04-21 16398946 core:Non-currentFinancialInstruments core:DisposalsDecreaseInProvisionsForImpairmentInvestments 2025-04-21 16398946 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments 2025-04-21 16398946 bus:Director1 2025-04-22 2026-03-31 16398946 bus:Director2 2025-04-22 2026-03-31

WARWICKER NEPHROLOGY LIMITED

Registered Number
16398946
(England and Wales)

Unaudited Financial Statements for the Period ended
31 March 2026

WARWICKER NEPHROLOGY LIMITED
Company Information
for the period from 22 April 2025 to 31 March 2026

Directors | MAYNARD, Linda Helen, Dr
| WARWICKER, Pawel, Dr

Company Secretary | MAYNARD, Linda Helen, Dr

Registered Address | Popples Close Farm Edge Lane
| Heptonstall
| Hebden Bridge
| HX7 7PG

Registered Number | 16398946 (England and Wales)

WARWICKER NEPHROLOGY LIMITED
Balance Sheet as at
31 March 2026

| Notes | 2026
--- | --- | ---
|  | £ |  | £
Current assets |  |  |  |
Debtors |  | 177 |  |
Cash at bank and on hand |  | 7,683 |  |
|  | 7,860 |  |
Creditors amounts falling due within one year |  | (5,349) |  |
Net current assets (liabilities) |  |  |  | 2,511
Total assets less current liabilities |  |  |  | 2,511
Net assets |  |  |  | 2,511
Capital and reserves |  |  |  |
Profit and loss account |  |  |  | 2,511
Shareholders' funds |  |  |  | 2,511

- The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
- The directors have chosen to not file a copy of the company’s profit and loss account under section 444 (5A) Companies Act 2006.
- The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).

The financial statements were approved and authorised for issue by the Board of Directors on 15 April 2026, and are signed on its behalf by:
WARWICKER, Pawel, Dr Director Registered Company No. 16398946

WARWICKER NEPHROLOGY LIMITED
Notes to the Financial Statements
for the period ended 31 March 2026

1. | Accounting policies
--- | ---

| Statutory information
--- | ---
| The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| Statement of compliance
--- | ---
| The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

| Basis of preparation
--- | ---
| The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

| Functional and presentation currency
--- | ---
| The financial statements are presented in sterling and this is the functional currency of the company.

| Going concern
--- | ---
| After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.

| Revenue from sale of goods
--- | ---
| Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.

| Current taxation
--- | ---
| Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.

2. | Average number of employees
--- | ---

|  | 2026
| Average number of employees during the year | 1

3. | Related party transactions
--- | ---
| During the year the directors made available a loan to the company. At the year end the balance of the loan was £1,644.